Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Regorafenib
100%
Risk Outcomes
100%
Patient Outcomes
100%
Risk-benefit
100%
Patient Benefit
100%
Drug Development
100%
Clinical Trials
100%
Patient Risk
100%
Drug Manufacturer
34%
Objective Response Rate
27%
Colorectal Cancer
24%
Overall Survival
24%
Embase
17%
Tolerability
17%
In Cancer
17%
New Indication
17%
Pooled Analysis
17%
PubMed
17%
Drug Efficacy
17%
Adverse Event Rates
17%
Solid Cancer
17%
Median Progression-free Survival
17%
Cochrane
17%
Repurposing
17%
Novel Chemotherapy
17%
Positive-negative
17%
Cumulative Risk
17%
Response Rate
17%
Hygiene Sanitation
16%
Laser-guided
16%
Inadequate Sanitation
16%
Emergency Use Authorization
11%
Single-arm Trial
10%
Ovid MEDLINE
10%
Misleading Reporting
10%
Impact-based
10%
High-quality Research
10%
Risk Profile
10%
Oncology Clinical Trials
10%
Oncologic
7%
Adverse Events
7%
Reagan
7%
Ladd's
7%
Adverse Event Profiles
7%
Positive Outcomes
7%
RECIST Criteria
7%
Objective Response
7%
Continued Use
7%
Cancer Clinical Trials
7%
Jordan
7%
Pharmacology, Toxicology and Pharmaceutical Science
Regorafenib
100%
Clinical Trial
100%
Drug Development
100%
Observational Study
50%
Coronavirinae
50%
Diseases
50%
Pharmaceutical Manufacturing
34%
Parasitosis
33%
Adverse Event
31%
Overall Survival
24%
Progression Free Survival
24%
Colorectal Carcinoma
24%
Female Infertility
20%
Vaccination
20%
Tolerability
17%
Chemotherapy Regimen
17%
Albendazole
16%
Malnutrition
16%
Messenger RNA
10%
Malignant Neoplasm
7%
Solid Malignant Neoplasm
7%
Pea
7%
Nursing and Health Professions
Osteoarthritis
50%
Surgery
50%
Quality of Life
50%
Misinformation
50%
Systematic Review
50%
Regorafenib
50%
COVID-19
50%
Meta Analysis
50%
Female Infertility
14%
Prevalence
10%
Embase
10%
Solid Malignant Neoplasm
7%
Chemotherapy
7%
Suture Anchor
7%
Messenger RNA
7%
Food and Drug Administration
7%
Social Media
7%
Medical Decision Making
7%
European Medicines Agency
7%
Vaccine Hesitancy
7%
BNT162b2 vaccine
7%